NATCOPHARM

. and partner Breckenridge Pharmaceutical launched generic Pomalidomide capsules in the US, a treatment for multiple myeloma and Kaposi sarcoma. The capsules are indicated for multiple myeloma patients who received at least two prior therapies, with estimated US sales of $3.2 billion. Natco Pharma holds 180 days of shared exclusivity based on FDA data.